The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration.
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label, five-way crossover study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
25
fexofenadine brand name
Tolerability
Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.
Time frame: Participants will be followed for the duration of study, an expected average of 5 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.